Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
JOURNAL OF ASTHMA
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2017-12-07
DOI
10.1080/02770903.2017.1379534
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Gary T Ferguson et al. Lancet Respiratory Medicine
- A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan
- (2016) Hae-Sim Park et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Reductions in eosinophil biomarkers by benralizumab in patients with asthma
- (2016) Tuyet-Hang Pham et al. RESPIRATORY MEDICINE
- Surgical ablation of atrial fibrillation: a protocol for a systematic review and meta-analysis of randomised controlled trials
- (2016) Graham R McClure et al. BMJ Open
- Targeted therapeutics for severe refractory asthma: monoclonal antibodies
- (2016) Christopher L. Grainge et al. Expert Review of Clinical Pharmacology
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
- (2016) Hector G Ortega et al. Lancet Respiratory Medicine
- A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma
- (2015) Richard M. Nowak et al. AMERICAN JOURNAL OF EMERGENCY MEDICINE
- Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma
- (2015) PD Mitchell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A summary of the new GINA strategy: a roadmap to asthma control
- (2015) Helen K. Reddel et al. EUROPEAN RESPIRATORY JOURNAL
- Targeting the interleukin pathway in the treatment of asthma
- (2015) Kian Fan Chung LANCET
- The immunology of asthma
- (2015) Bart N Lambrecht et al. NATURE IMMUNOLOGY
- Associations of Three Well-Characterized Polymorphisms in the IL-6 and IL-10 Genes with Pneumonia: A Meta-Analysis
- (2015) Hong Chen et al. Scientific Reports
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
- (2014) Pranabashis Haldar et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Asthma: pathogenesis and novel drugs for treatment
- (2014) J. T. Olin et al. BMJ-British Medical Journal
- Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
- (2014) Mario Castro et al. Lancet Respiratory Medicine
- Monoclonal antibodies for the treatment of refractory asthma
- (2013) Nathan Hambly et al. CURRENT OPINION IN PULMONARY MEDICINE
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Genetic Polymorphism of Matrix Metalloproteinase Family and Chronic Obstructive Pulmonary Disease Susceptibility: a Meta-analysis
- (2013) Hongbin Zhou et al. Scientific Reports
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
- Asthma phenotypes: the evolution from clinical to molecular approaches
- (2012) Sally E Wenzel NATURE MEDICINE
- Reslizumab for Poorly Controlled, Eosinophilic Asthma
- (2011) Mario Castro et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
- (2011) Aasia Ghazi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
- (2010) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Eosinophils and allergic airway disease: there is more to the story
- (2009) Elizabeth R. Walsh et al. TRENDS IN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More